Literature DB >> 11850276

In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters.

R Zbinden1, V Pünter, A von Graevenitz.   

Abstract

The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244 strains of gram-negative nonfermenters were evaluated. The overall MIC at which 50% of isolates are inhibited (MIC50) and the overall MIC90 were 2 and 64 microg/ml, respectively, which are similar to those of imipenem, lower than those of the other cephalosporins tested, amoxicillin, and the ticarcillin-clavulanic acid combination, and much higher than those of ciprofloxacin. BAL9141 shows species-dependent activity in vitro against a variety of gram-negative nonfermentative pathogens.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850276      PMCID： PMC127485          DOI： 10.1128/AAC.46.3.872-875.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.

Authors:  R N Jones; M A Pfaller; G V Doern; M E Erwin; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1998-03       Impact factor: 2.803

2.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

4.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae.

Authors:  O Klein; N X Chin; H B Huang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191
  5 in total
  10 in total

1.  Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

Authors:  Todd A Davies; Wenchi Shang; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

3.  Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Authors:  Thomas P Lodise; Rienk Pypstra; James B Kahn; Bindu P Murthy; Hui C Kimko; Karen Bush; Gary J Noel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

4.  Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Authors:  Todd A Davies; Malcolm G P Page; Wenchi Shang; Ted Andrew; Malgosia Kania; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

5.  Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Sandrine Lemaire; Youri Glupczynski; Valérie Duval; Bernard Joris; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

Review 6.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Authors:  Anne Marie Queenan; Wenchi Shang; Malgosia Kania; Malcolm G P Page; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

8.  Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Authors:  César Bustos; Jose L Del Pozo
Journal:  Infect Drug Resist       Date:  2010-04-22       Impact factor: 4.003

9.  In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens.

Authors:  K M Kumar; P Anitha; V Sivasakthi; Susmita Bag; P Lavanya; Anand Anbarasu; Sudha Ramaiah
Journal:  3 Biotech       Date:  2013-06-11       Impact factor: 2.406

Review 10.  The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Authors:  Jonathan Turner; Alyssa Muraoka; Michael Bedenbaugh; Blaine Childress; Lauren Pernot; Mark Wiencek; Yuri K Peterson
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.